PE20161236A1 - Compuesto de triazina y su uso para fines medicos - Google Patents

Compuesto de triazina y su uso para fines medicos

Info

Publication number
PE20161236A1
PE20161236A1 PE2016001506A PE2016001506A PE20161236A1 PE 20161236 A1 PE20161236 A1 PE 20161236A1 PE 2016001506 A PE2016001506 A PE 2016001506A PE 2016001506 A PE2016001506 A PE 2016001506A PE 20161236 A1 PE20161236 A1 PE 20161236A1
Authority
PE
Peru
Prior art keywords
halogen
hydroxy
triazine compound
medical purposes
triazin
Prior art date
Application number
PE2016001506A
Other languages
English (en)
Spanish (es)
Inventor
Takahiro Hotta
Ikuo Mitani
Masaki Yamashita
Yuichi Nakagawa
Masatoshi Ueda
Hironobu Nagamori
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of PE20161236A1 publication Critical patent/PE20161236A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/22—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to two ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2016001506A 2014-02-20 2015-02-19 Compuesto de triazina y su uso para fines medicos PE20161236A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2014031035 2014-02-20

Publications (1)

Publication Number Publication Date
PE20161236A1 true PE20161236A1 (es) 2016-11-23

Family

ID=53878341

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2021000546A PE20211548A1 (es) 2014-02-20 2015-02-19 Compuesto de triazina y su uso para fines medicos
PE2016001506A PE20161236A1 (es) 2014-02-20 2015-02-19 Compuesto de triazina y su uso para fines medicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2021000546A PE20211548A1 (es) 2014-02-20 2015-02-19 Compuesto de triazina y su uso para fines medicos

Country Status (32)

Country Link
US (3) US20150266834A1 (enExample)
EP (2) EP3456713A1 (enExample)
JP (4) JP6461637B2 (enExample)
KR (1) KR102360699B1 (enExample)
CN (1) CN106232585B (enExample)
AR (1) AR099498A1 (enExample)
AU (1) AU2015219920B2 (enExample)
BR (1) BR112016018341B1 (enExample)
CA (1) CA2936408C (enExample)
CL (1) CL2016002091A1 (enExample)
CY (1) CY1121261T1 (enExample)
DK (1) DK3109240T3 (enExample)
ES (1) ES2704922T3 (enExample)
HR (1) HRP20182134T1 (enExample)
IL (1) IL247319B (enExample)
LT (1) LT3109240T (enExample)
MX (1) MX369217B (enExample)
MY (1) MY183605A (enExample)
PE (2) PE20211548A1 (enExample)
PH (1) PH12016501651B1 (enExample)
PL (1) PL3109240T3 (enExample)
PT (1) PT3109240T (enExample)
RS (1) RS58235B1 (enExample)
RU (1) RU2692789C2 (enExample)
SA (1) SA516371701B1 (enExample)
SG (1) SG11201606902QA (enExample)
SI (1) SI3109240T1 (enExample)
SM (1) SMT201800684T1 (enExample)
TR (1) TR201821158T4 (enExample)
TW (1) TWI651310B (enExample)
WO (1) WO2015125842A1 (enExample)
ZA (1) ZA201606449B (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
CN107108467B (zh) * 2014-12-24 2022-08-19 北京生命科学研究所 细胞坏死抑制剂
US11078412B2 (en) * 2015-03-04 2021-08-03 Shimadzu Corporation Polyamine and tyramine analysis method using pyrene containing fluorescence derivatization reagent and excimer fluorescence
EP3339296A4 (en) 2015-08-17 2019-01-23 Japan Tobacco, Inc. HYDROXYTRIAZINE COMPOUND AND USE THEREOF IN MEDICINE
AU2016346557B2 (en) * 2015-10-29 2020-10-29 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative
GB201603311D0 (en) * 2016-02-25 2016-04-13 Jakobsson Per Johan New uses and methods
KR102503590B1 (ko) * 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
CA3031563C (en) 2016-08-01 2023-12-05 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
CN110799506B (zh) * 2017-06-26 2024-03-01 默克专利有限公司 用于制备被取代的含氮杂环化合物的方法
CN114502163A (zh) * 2019-07-22 2022-05-13 安吉昂生物医药公司 作为rho相关卷曲螺旋激酶(rock)抑制剂的乙炔基杂环
US11786538B2 (en) * 2019-12-11 2023-10-17 Somerset Therapeutics, Llc Low benzalkonium chloride bimatoprost ophthalmic compositions with effective penetration and preservation properties
KR102157466B1 (ko) * 2020-05-19 2020-09-17 동아대학교 산학협력단 헥사하이드로트리아진 유도체를 포함하는 방광암의 예방, 개선 또는 치료용 조성물
JP7277676B2 (ja) 2021-02-02 2023-05-19 あすか製薬株式会社 ピリミジン誘導体
EP4553068A1 (en) 2022-07-06 2025-05-14 ASKA Pharmaceutical Co., Ltd. Pyrimidine derivatives

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH473818A (de) 1964-03-18 1969-06-15 Ciba Geigy Verfahren zur Herstellung von neuen Hydroxyphenyl-1,3,5-triazinen und deren Verwendung
WO1981003020A1 (en) * 1980-04-22 1981-10-29 Commw Scient Ind Res Org Triazine synthesis
SU1313854A1 (ru) 1985-04-17 1987-05-30 Институт Органической Химии Ан Армсср Способ получени смеси 2-оксо-2,3-дигидро-4,6,-бис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина и 2,4,6-трис-(3 @ -диэтиламинометилен-4 @ -оксифенил)-1,3,5-триазина
DE19543730A1 (de) * 1995-11-23 1997-05-28 Ciba Geigy Ag Bis-Resorcinyl-Triazine
US6410729B1 (en) 1996-12-05 2002-06-25 Amgen Inc. Substituted pyrimidine compounds and methods of use
BR9713850A (pt) * 1996-12-05 2000-02-29 Amgen Inc Composto, composição farmacêutica, processos para profilaxia ou tratamento de infecção e de doenças, para diminuir concentrações no plasma de qualquer um ou de ambos tnf-. e o;-1 de qualquer um ou de ambos il-6 e il-8, para profilaxia ou tratamento da doença diabetes e de um distúrbio da dor em um mamìfero, para dimunuir a produção de prostaglandinas em um mamìfero, e, para dimuir a atividade da enzima ciclooxigenase em um mamìfero.
JP2002514195A (ja) 1996-12-05 2002-05-14 アムジエン・インコーポレーテツド 置換ピリミジン化合物およびそれの使用
ZA9710727B (en) 1996-12-05 1998-06-12 Amgen Inc Substituted pyrimidine compounds and methods of use.
US6096753A (en) 1996-12-05 2000-08-01 Amgen Inc. Substituted pyrimidinone and pyridone compounds and methods of use
GB9726987D0 (en) 1997-12-22 1998-02-18 Glaxo Group Ltd Compounds
TR200102810T2 (tr) 1999-04-01 2002-01-21 Pfizer Products Inc. Sorbitol dehidrojenaz inhibitörleri olarak aminopirimidinler
WO2004000820A2 (en) * 2002-06-21 2003-12-31 Cellular Genomics, Inc. Certain aromatic monocycles as kinase modulators
KR101538811B1 (ko) 2007-04-03 2015-07-22 이 아이 듀폰 디 네모아 앤드 캄파니 치환된 벤젠 살진균제
BRPI0913343B1 (pt) 2008-06-04 2018-01-23 Adeka Corporation Método para produção do composto 2,4,6-tri (hidroxifenil)-1,3,5-triazina
JP5388270B2 (ja) 2008-06-04 2014-01-15 株式会社Ａｄｅｋａ ２，４，６−トリス（ヒドロキシフェニル）−１，３，５−トリアジン化合物の製造方法
EP2138488A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
CN101747282A (zh) * 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
AR077999A1 (es) 2009-09-02 2011-10-05 Vifor Int Ag Antagonistas de pirimidin y triazin-hepcidina
AU2010298720B2 (en) * 2009-09-23 2015-07-23 Albert Einstein College Of Medicine, Inc. Prostaglandin transporter inhibitors and uses thereof
WO2011048004A1 (en) 2009-10-23 2011-04-28 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin e2 synthase-1
US8586604B2 (en) 2010-08-20 2013-11-19 Boehringer Ingelheim International Gmbh Inhibitors of the microsomal prostaglandin E2 synthase-1
AR086254A1 (es) * 2011-05-26 2013-11-27 Lilly Co Eli Derivados de imidazol utiles para el tratamiento de artritis
FR2983859B1 (fr) * 2011-12-12 2014-01-17 Sanofi Sa Derives de 1,3,5-triazine-2-amine, leur preparation et leur application en diagnostique et en therapeutique
SI2800743T1 (en) * 2012-01-06 2018-08-31 Agios Pharmaceuticals, Inc. Therapeutically active compounds and methods for their use
AU2013265266A1 (en) 2012-05-23 2015-01-15 Stemergie Biotechnology Sa Inhibitors of the activity of complex (III) of the mitochondrial electron transport chain and use thereof
TWI568722B (zh) 2012-06-15 2017-02-01 葛蘭馬克製藥公司 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物
JP2014031035A (ja) 2012-08-01 2014-02-20 Yamaha Motor Co Ltd 原動機付き鞍乗型車両
WO2015059618A1 (en) * 2013-10-22 2015-04-30 Glenmark Pharmaceuticals S.A. SUBSTITUTED PYRIMIDINE COMPOUNDS AS mPGES-1 INHIBITORS
TWI651310B (zh) * 2014-02-20 2019-02-21 日商日本煙草產業股份有限公司 三化合物及其醫藥用途
CN105586773A (zh) * 2014-11-13 2016-05-18 东丽纤维研究所（中国）有限公司 一种拒水抗紫外纺织品及其生产方法和用途
EP3339296A4 (en) 2015-08-17 2019-01-23 Japan Tobacco, Inc. HYDROXYTRIAZINE COMPOUND AND USE THEREOF IN MEDICINE
AU2016346557B2 (en) * 2015-10-29 2020-10-29 Aska Pharmaceutical Co., Ltd. Pyrimidine derivative

Also Published As

Publication number Publication date
RU2016137263A3 (enExample) 2018-10-04
CN106232585A (zh) 2016-12-14
BR112016018341A2 (enExample) 2017-08-08
EP3109240B1 (en) 2018-10-24
US20230011968A1 (en) 2023-01-12
AU2015219920A1 (en) 2016-07-14
EP3456713A1 (en) 2019-03-20
JP6461637B2 (ja) 2019-01-30
ES2704922T3 (es) 2019-03-20
WO2015125842A1 (ja) 2015-08-27
US20200087266A1 (en) 2020-03-19
RU2692789C2 (ru) 2019-06-27
TWI651310B (zh) 2019-02-21
RS58235B1 (sr) 2019-03-29
JP2021054856A (ja) 2021-04-08
KR102360699B1 (ko) 2022-02-10
PT3109240T (pt) 2019-01-21
CA2936408A1 (en) 2015-08-27
SG11201606902QA (en) 2016-09-29
SMT201800684T1 (it) 2019-01-11
PH12016501651A1 (en) 2017-02-06
SI3109240T1 (sl) 2019-02-28
MY183605A (en) 2021-03-02
PH12016501651B1 (en) 2017-02-06
TR201821158T4 (tr) 2019-01-21
EP3109240A1 (en) 2016-12-28
JP2015172039A (ja) 2015-10-01
CL2016002091A1 (es) 2017-01-20
AR099498A1 (es) 2016-07-27
HRP20182134T1 (hr) 2019-02-08
EP3109240A4 (en) 2017-07-26
CY1121261T1 (el) 2020-05-29
DK3109240T3 (en) 2018-12-17
US20150266834A1 (en) 2015-09-24
MX369217B (es) 2019-10-31
ZA201606449B (en) 2017-11-29
CN106232585B (zh) 2019-04-02
NZ721718A (en) 2021-08-27
MX2016010875A (es) 2016-10-26
US12398111B2 (en) 2025-08-26
KR20160113727A (ko) 2016-09-30
IL247319B (en) 2019-11-28
PL3109240T3 (pl) 2019-03-29
JP2019065036A (ja) 2019-04-25
RU2016137263A (ru) 2018-03-23
AU2015219920B2 (en) 2018-12-20
CA2936408C (en) 2022-09-13
JP2022120173A (ja) 2022-08-17
TW201620881A (zh) 2016-06-16
SA516371701B1 (ar) 2019-01-21
LT3109240T (lt) 2019-01-10
BR112016018341B1 (pt) 2023-02-07
PE20211548A1 (es) 2021-08-16
IL247319A0 (en) 2016-09-29

Similar Documents

Publication Publication Date Title
PE20161236A1 (es) Compuesto de triazina y su uso para fines medicos
CY1123994T1 (el) Δικυκλικες-συντηγμενες ενωσεις ετεροαρυλιου ή αρυλιου ως ρυθμιστες της irak4
CY1121694T1 (el) Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
EA201791304A1 (ru) Производные изохинолина для лечения вич
PE20161438A1 (es) Inhibidores de desmetilasa 1 especifica a lisina
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
PE20170666A1 (es) 2-(morfolin-4-il)-1,7-naftiridinas
PE20170268A1 (es) Compuestos de heteroarilo para la inhibicion de cinasa
PE20191541A1 (es) Composiciones y metodos para inhibir la accion de la arginasa
PE20161384A1 (es) Ciclopropilaminas como inhibidores de lsd 1
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
PH12016501440A1 (en) Novel heterocyclic compounds
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
MX377916B (es) Compuestos 4-amino-imidazoquinolina.
CY1123494T1 (el) Enωσeiς etepoapyλo-kapboξamiδioy ως anaσtoλeiς thς ripk2
PE20170662A1 (es) Compuestos de aminopiridiloxipirazol
MX388321B (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
PH12016502394A1 (en) 1, 3, 4-thiadiazole compounds and their use in treating cancer
CY1122077T1 (el) Νεα δακτυλιωμενα φαινοξυακεταμιδια
TN2017000158A1 (en) Carbazole derivatives
PE20191142A1 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
MX390051B (es) Antagonistas de ep4.
EA201591649A1 (ru) Составы с органическими соединениями